Cellectis Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cellectis stock.
View analyst ratings for Cellectis or view top-rated stocks.

Wall Street analysts have given Cellectis a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cellectis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Cellectis saw a decrease in short interest in the month of January. As of January 29th, there was short interest totaling 438,700 shares, a decrease of 28.6% from the January 14th total of 614,200 shares. Based on an average trading volume of 425,000 shares, the days-to-cover ratio is currently 1.0 days. Approximately 1.0% of the company's stock are short sold.
View Cellectis' Short Interest.

Cellectis is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Cellectis.

Cellectis S.A. (NASDAQ:CLLS) issued its earnings results on Thursday, March, 4th. The biotechnology company reported ($0.95) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.01) by $0.06. Cellectis had a negative net margin of 110.52% and a negative trailing twelve-month return on equity of 23.56%.
View Cellectis' earnings history.

Cellectis' stock was trading at $11.43 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CLLS stock has increased by 59.1% and is now trading at $18.19.
View which stocks have been most impacted by COVID-19.

4 equities research analysts have issued twelve-month price targets for Cellectis' shares. Their forecasts range from $21.00 to $33.00. On average, they expect Cellectis' share price to reach $28.67 in the next year. This suggests a possible upside of 57.6% from the stock's current price.
View analysts' price targets for Cellectis or view top-rated stocks among Wall Street analysts.

4 employees have rated Cellectis CEO André Choulika on Glassdoor.com. André Choulika has an approval rating of 100% among Cellectis' employees. This puts André Choulika in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Cellectis include Revolution Medicines (RVMD), NantKwest (NK), Editas Medicine (EDIT), NanoString Technologies (NSTG), Sorrento Therapeutics (SRNE), Kymera Therapeutics (KYMR), Bavarian Nordic A/S (BVNRY), AlloVir (ALVR), BioCryst Pharmaceuticals (BCRX), Vericel (VCEL), bluebird bio (BLUE), Scholar Rock (SRRK), C4 Therapeutics (CCCC), Translate Bio (TBIO) and Ocugen (OCGN).
View all of CLLS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Gilead Sciences (gild), Calyxt (CLXT), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Intel (INTC) and Sorrento Therapeutics (SRNE).

(CLLS) raised $129 million in an initial public offering on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Cellectis' stock is owned by many different institutional and retail investors. Top institutional investors include Credit Suisse AG (2.83%), Sumitomo Mitsui Trust Holdings Inc. (1.82%), Nikko Asset Management Americas Inc. (1.82%), Morgan Stanley (0.72%), BlackRock Inc. (0.37%) and Kennedy Capital Management Inc. (0.28%).

CLLS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., Eqis Capital Management Inc., Aperio Group LLC, Citigroup Inc., Princeton Capital Management LLC, Wells Fargo & Company MN, and Kennedy Capital Management Inc..

CLLS stock was purchased by a variety of institutional investors in the last quarter, including Credit Suisse AG, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Vontobel Holding Ltd., Capital Impact Advisors LLC, KBC Group NV, OneAscent Wealth Management LLC, and Exchange Traded Concepts LLC.

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLLS stock can currently be purchased for approximately $18.19.

Cellectis has a market capitalization of $772.82 million and generates $22.99 million in revenue each year. The biotechnology company earns $-102,090,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis.

Cellectis employs 253 workers across the globe.

The official website for Cellectis is www.cellectis.com.

Cellectis is headquartered at 8 RUE DE LA CROIX JARRY, PARIS I0, 75013.

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]